| Liprin Protein | |
|---|---|
| Gene | PPFIA1 |
| UniProt | Q13136 |
| PDB | 5E45 |
| Mol. Weight | 175 kDa |
| Localization | Presynaptic active zone, dendritic spines, postsynaptic density |
| Family | Liprin family, LAR-RPTP interacting proteins |
| Diseases | Alzheimer's Disease, Parkinson's Disease, ALS |
Liprin (also known as Liprin-alpha or LAR-RPTP interacting protein) is a family of scaffolding proteins that play essential roles in synapse development, function, and plasticity[^1]. The liprin family consists of multiple isoforms (liprin-alpha1-4 and liprin-beta), each with distinct expression patterns and functions[^2].
The PPFIA1 gene encodes liprin-alpha1, the founding member of the family. Liprins are characterized by their ability to interact with LAR (Leukocyte common antigen-related) receptor protein tyrosine phosphatases and their role in orchestrating synaptic protein complexes[^3].
Liprin proteins contain multiple protein-interacting domains:
The N-terminal region contains coiled-coil motifs that mediate homomeric and heteromeric dimerization between liprin family members.
The central region contains the critical LAR-RPTP binding domain, which is essential for liprin's synaptic functions.
The C-terminal region contains sterile alpha motif (SAM) domains that mediate additional protein-protein interactions[^4].
Liprin plays critical roles in excitatory synapse development:
In the presynaptic terminal, liprin interacts with:
Liprins mediate synaptic adhesion by bridging presynaptic and postsynaptic proteins, ensuring proper synaptic contact formation and maintenance[^5].
Liprin-alpha is involved in amyloid precursor protein (APP) processing and may modulate amyloid-beta production. Changes in liprin expression have been observed in AD brains[^6].
Liprin interactions with synaptic proteins may be altered in PD, affecting dopaminergic synapse function and stability[^7].
Mutations in liprin-related genes have been implicated in some cases of ALS, highlighting the importance of synaptic scaffolding in motor neuron disease[^8].
Therapeutic approaches include: